NASDAQ:LSB LakeShore Biopharma (LSB) Stock Price, News & Analysis $0.83 -0.01 (-0.84%) Closing price 08/22/2025 03:58 PM EasternExtended Trading$0.82 -0.01 (-0.60%) As of 08/22/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LakeShore Biopharma Stock (NASDAQ:LSB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LakeShore Biopharma alerts:Sign Up Key Stats Today's Range$0.81▼$0.8350-Day Range$0.66▼$1.3852-Week Range$0.59▼$8.60Volume5,242 shsAverage Volume75,822 shsMarket Capitalization$17.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China. Read More LakeShore Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreLSB MarketRank™: LakeShore Biopharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 890th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LakeShore Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioLakeShore Biopharma has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.19% of the float of LakeShore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeShore Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LakeShore Biopharma has recently decreased by 58.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakeShore Biopharma does not currently pay a dividend.Dividend GrowthLakeShore Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.19% of the float of LakeShore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeShore Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LakeShore Biopharma has recently decreased by 58.00%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for LakeShore Biopharma this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LakeShore Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of LakeShore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LakeShore Biopharma's insider trading history. Receive LSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LakeShore Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LSB Stock News HeadlinesLakeShore Biopharma receives non-binding acquisition proposal from OceanpineAugust 18, 2025 | msn.comLakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details InsideAugust 18, 2025 | msn.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.August 24 at 2:00 AM | Golden Portfolio (Ad)LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the CompanyAugust 18, 2025 | prnewswire.comLakeShore Biopharma Reports FY2025 Financial Results with Improved ProfitabilityAugust 8, 2025 | theglobeandmail.comLakeShore Biopharma Announces Fiscal Year 2025 Financial ResultsJuly 31, 2025 | prnewswire.comLakeShore Biopharma secures $15 million in private placementJuly 10, 2025 | uk.investing.comLakeShore Biopharma Announces US$15 Million Private Placement FinancingJuly 8, 2025 | prnewswire.comSee More Headlines LSB Stock Analysis - Frequently Asked Questions How have LSB shares performed this year? LakeShore Biopharma's stock was trading at $3.46 at the start of the year. Since then, LSB stock has decreased by 76.0% and is now trading at $0.8290. When did LakeShore Biopharma's stock split? LakeShore Biopharma's stock reverse split on Friday, October 4th 2024.The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are LakeShore Biopharma's major shareholders? LakeShore Biopharma's top institutional shareholders include Orbimed Advisors LLC (0.26%). How do I buy shares of LakeShore Biopharma? Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LakeShore Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that LakeShore Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Today8/24/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSB Previous SymbolNASDAQ:LSB CIK1946399 WebN/A Phone17327133678FaxN/AEmployees773Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio1.02 Quick Ratio0.75 Sales & Book Value Annual Sales$85.67 million Price / Sales0.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book0.25Miscellaneous Outstanding Shares20,770,000Free FloatN/AMarket Cap$17.22 million OptionableN/A Beta0.56 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:LSB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.